FluChip‐8G Insight : HA and NA subtyping of potentially pandemic influenza A viruses in a single assay
Abstract Background Global influenza surveillance in humans and animals is a critical component of pandemic preparedness. The FluChip‐8G Insight assay was developed to subtype both seasonal and potentially pandemic influenza viruses in a single assay with a same day result. FluChip‐8G Insight uses whole gene segment RT‐PCR‐based amplification to provide robustness against genetic drift and subsequent microarray detection with artificial neural network‐based data interpretation. Objectives The objective of this study was to verify and validate the performance of the FluChip‐8G Insight assay for the detection and positive identification of human and animal origin non‐seasonal influenza A specimens. Methods We evaluated the ability of the FluChip‐8G Insight technology to type and HA and NA subtype a sample set consisting of 297 results from 180 unique non‐seasonal influenza A strains (49 unique subtypes). Results FluChip‐8G Insight demonstrated a positive percent agreement ≥93% for 5 targeted HA and 5 targeted NA subtypes except for H9 (88%), and negative percent agreement exceeding 95% for all targeted subtypes. Conclusions The FluChip‐8G Insight neural network‐based algorithm used for virus identification performed well over a data set of 297 naïve sample results, and can be easily updated to improve performance on emerging strains without changing the underlying assay chemistry..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Influenza and Other Respiratory Viruses - 14(2020), 1, Seite 55-60 |
| Beteiligte Personen: |
Toth, Evan [VerfasserIn] |
|---|
| Anmerkungen: |
© 2020 John Wiley & Sons Ltd |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1111/irv.12683 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY00758749X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY00758749X | ||
| 003 | DE-627 | ||
| 005 | 20230307171740.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/irv.12683 |2 doi | |
| 028 | 5 | 2 | |a IRV_IRV12683.xml |
| 035 | |a (DE-627)WLY00758749X | ||
| 035 | |a (WILEY)IRV12683 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Toth, Evan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a FluChip‐8G Insight |b HA and NA subtyping of potentially pandemic influenza A viruses in a single assay |
| 264 | 1 | |c 2020 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2020 John Wiley & Sons Ltd | ||
| 520 | |a Abstract Background Global influenza surveillance in humans and animals is a critical component of pandemic preparedness. The FluChip‐8G Insight assay was developed to subtype both seasonal and potentially pandemic influenza viruses in a single assay with a same day result. FluChip‐8G Insight uses whole gene segment RT‐PCR‐based amplification to provide robustness against genetic drift and subsequent microarray detection with artificial neural network‐based data interpretation. Objectives The objective of this study was to verify and validate the performance of the FluChip‐8G Insight assay for the detection and positive identification of human and animal origin non‐seasonal influenza A specimens. Methods We evaluated the ability of the FluChip‐8G Insight technology to type and HA and NA subtype a sample set consisting of 297 results from 180 unique non‐seasonal influenza A strains (49 unique subtypes). Results FluChip‐8G Insight demonstrated a positive percent agreement ≥93% for 5 targeted HA and 5 targeted NA subtypes except for H9 (88%), and negative percent agreement exceeding 95% for all targeted subtypes. Conclusions The FluChip‐8G Insight neural network‐based algorithm used for virus identification performed well over a data set of 297 naïve sample results, and can be easily updated to improve performance on emerging strains without changing the underlying assay chemistry. | ||
| 700 | 1 | |a Dawson, Erica D. |4 aut | |
| 700 | 1 | |a Taylor, Amber W. |4 aut | |
| 700 | 1 | |a Stoughton, Robert S. |4 aut | |
| 700 | 1 | |a Blair, Rebecca H. |4 aut | |
| 700 | 1 | |a Johnson, James E. Jr. |4 aut | |
| 700 | 1 | |a Slinskey, Amelia |4 aut | |
| 700 | 1 | |a Fessler, Ryan |4 aut | |
| 700 | 1 | |a Smith, Catherine B. |4 aut | |
| 700 | 1 | |a Talbot, Sarah |4 aut | |
| 700 | 1 | |a Rowlen, Kathy |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and Other Respiratory Viruses |g 14(2020), 1, Seite 55-60 |w (DE-627)WLY007586981 |x 17502659 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:1 |g pages:55-60 |g extent:6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 1 |h 55-60 |g 6 | ||